A Feasibility Study of the Nativis Voyager® System in Patients With Recurrent Glioblastoma Multiforme (GBM)
Trial Summary
Do I have to stop taking my current medications for the trial?
The trial protocol does not specify if you need to stop taking your current medications. However, you cannot participate if you are currently being treated with other investigational agents or have received other investigational therapy within the last 28 days.
What is the purpose of this trial?
This trial will test a new treatment called Nativis Voyager therapy in patients with recurring brain cancer who haven't responded to or can't tolerate standard treatments. The treatment uses special waves to attack cancer cells, combined with drugs that stop cancer cells from multiplying and prevent tumors from getting nutrients. Up to 32 patients will be treated to see if this approach is safe and useful. The Nativis Voyager® device has been previously evaluated in patients with recurrent glioblastoma, showing promising results with no significant side effects reported.
Research Team
Donna Morgan Murray, PhD
Principal Investigator
Nativis, Inc.
Eligibility Criteria
Inclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive Nativis Voyager therapy with lomustine, with or without bevacizumab, until tumor progression
Follow-up
Participants are monitored for safety and effectiveness after treatment
Long-term follow-up
Participants are monitored for progression-free survival and overall survival
Treatment Details
Interventions
- Nativis Voyager RFE Therapy
Find a Clinic Near You
Who Is Running the Clinical Trial?
Nativis, Inc.
Lead Sponsor